Fortress Biotech (NASDAQ: FBIO) extends loan maturity and grants warrants

Rhea-AI Filing Summary

Fortress Biotech, Inc. entered into a first amendment to its term loan credit agreement with Oaktree Fund Administration that extends the loan maturity, adjusts covenants and grants new stock warrants to the lenders. The company initially borrowed $35.0 million under the facility in July 2024 and currently has about $29.5 million outstanding.

The amendment moves the loan’s maturity from July 25, 2027 to June 30, 2028, with quarterly interest payments until maturity. Principal will be repaid based on the outstanding balance as of September 30, 2027: 12.5% due on September 30, 2027, another 12.5% on December 31, 2027, 37.5% on March 31, 2028, and the remaining 37.5% at maturity.

Journey Medical Corporation, a controlled subsidiary, is now subject to higher minimum product net sales covenants, rising from $60.0 million at December 31, 2025 to $80.0 million at December 31, 2026 and each quarter-end thereafter, with an event of default possible if these levels are not met while loan principal exceeds $10.0 million. In connection with the amendment, Fortress granted warrants to purchase up to 600,000 common shares at $2.62 per share, with anti-dilution and price-reset features, immediately exercisable through July 25, 2031 and issued as unregistered securities under Section 4(a)(2), with a planned resale registration.

Insights

Debt and capital structure analyst

Fortress extends its Oaktree term loan and adds equity-linked warrants and tighter sales covenants.

Fortress Biotech amended its credit agreement with Oaktree covering a term loan that initially provided $35.0 million, with up to an additional $15.0 million available subject to lender consent, and has $29.5 million outstanding. The amendment extends the final maturity from July 25, 2027 to June 30, 2028, keeps interest-only payments until maturity, and backloads principal into four installments tied to the balance as of September 30, 2027, culminating in 37.5% of that amount due at maturity.

For credit protection, the lenders revised the minimum product net sales covenant for Journey Medical Corporation. The required trailing twelve-month product net sales step from $60.0 million at the quarter ending December 31, 2025 up to $80.0 million by the quarter ending December 31, 2026 and thereafter, with failure constituting an event of default, subject to specified cure rights, when the outstanding principal exceeds $10.0 million. This ties loan compliance directly to Journey’s ability to generate and sustain higher revenue levels over time.

To compensate lenders, Fortress issued warrants to purchase up to 600,000 common shares at an exercise price of $2.62 per share, immediately exercisable and expiring on July 25, 2031. The warrants include customary anti-dilution adjustments and a price-reset feature if future equity is issued below the then-current exercise price, as well as a net exercise option and a commitment to register the resale of the underlying shares. Overall, the changes combine extended debt duration with additional equity-linked exposure for lenders and more demanding operating covenants for the borrower.

8-K Event Classification

3 items: 1.01, 2.03, 3.02

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Understanding 8-K Material Events →

0001429260false0001429260us-gaap:CommonStockMember2025-12-122025-12-120001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2025-12-122025-12-1200014292602025-12-122025-12-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 12, 2025

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

​

Delaware
 (State or Other Jurisdiction
of Incorporation)   ​ ​ 001-35366
 (Commission File Number)   ​ ​ ​ 20-5157386
(IRS Employer
Identification No.)

​

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL 33154

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act.

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	FBIO	Nasdaq Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock	FBIOP	Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 1.01.    Entry into a Material Definitive Agreement.

​

On December 12, 2025, Fortress Biotech, Inc. (the “Company”), as borrower, entered into the First Amendment to Credit Agreement (the “Amendment”), which amends that certain Credit Agreement dated July 25, 2024 (the “Agreement”) with Oaktree Fund Administration, LLC, as the administrative agent (in such capacity, the “Agent”), and the lenders from time to time party thereto. The Company initially borrowed $35.0 million under the Agreement on in July 2024 and is eligible to draw up to an additional $15.0 million with the lenders’ consent (together, the “Loan”). As of the date of this report, the Company currently has approximately $29.5 million outstanding under the Loan. 

​

Under the terms of the Amendment, the Loan’s maturity date was extended from July 25, 2027 to June 30, 2028. The Company is required to make quarterly interest payments until the maturity date and the Amendment also modified the principal repayment schedule of the Loan, which will now be in accordance with the following schedule: 12.5% of the outstanding principal balance of the Loan as of September 30, 2027 due on September 30, 2027, 12.5% of the outstanding principal balance of the Loan as of September 30, 2027 due on December 31, 2027, 37.5% of the outstanding principal balance of the Loan as of September 30, 2027 due on March 31, 2028, and the remaining 37.5% of the outstanding principal amount of the Loan as of September 30, 2027 due on the maturity date of June 30, 2028.

The Amendment also amended the financial covenant requiring that product net sales of Journey Medical Corporation (“Journey”), a controlled subsidiary of the Company, meet a consolidated minimum net sales amount on a trailing twelve-month basis, tested quarterly (the “Minimum Net Sales Test”). Under the Amendment, the Minimum Net Sales Test now requires that Journey’s product net sales be: $60.0 million as of the last day of the fiscal quarter ending December 31, 2025, $65.0 million as of the last day of the fiscal quarter ending March 31, 2026, $70.0 million as of the last day of the fiscal quarter ending June 30, 2026, $75.0 million as of the last day of the fiscal quarter ending September 30, 2026, and $80.0 million as of the fiscal quarter ending December 31, 2026 and the last day of each fiscal quarter thereafter. Failure by the Company to comply with the Minimum Net Sales Test will result in an event of default, subject to certain cure rights of the Company with respect to the Minimum Net Sales Test. The Minimum Net Sales Test covenant does not apply any time the outstanding principal balance of the Loan is less than or equal to $10.0 million.

​

In connection with the Amendment, the Company granted warrants to the lenders to purchase up to 600,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $2.62 per share (the “Warrants”). The Warrants contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offerings and pro rata distributions. The exercise price of the Warrants will also be adjusted if, while the Warrants are outstanding, the Company engages in any transaction involving the issuance or sale of shares of Common Stock or equivalent securities at an effective price per share less than the exercise price of the Warrants then in effect (such lower price, the “Base Share Price”). In such case, the exercise price of the Warrants will be reduced to equal the Base Share Price. The Warrants are immediately exercisable, will expire on July 25, 2031 and may be net exercised for no cash payment at the holder’s election. The Company also agreed to file a registration statement to register the resale of the shares of Common Stock issuable upon exercise of the Warrants.

​

The foregoing descriptions of the Warrants and the Amendment are subject to, and qualified in their entirety by, such documents (or forms thereof), to be filed with a subsequent periodic report of the Company.

​

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated by reference under this Item 2.03.

​

Item 3.02. Unregistered Sale of Equity Securities.

​

The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Warrants is incorporated by reference under this Item 3.02. The Warrants are being issued in a transaction that is exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	Fortress Biotech, Inc.
​	(Registrant)
​	​
Date: December 15, 2025
​	​	​
	By:	/s/ David Jin
		David Jin
		Chief Financial Officer

​

​

​

​

​

FAQ

What credit agreement did Fortress Biotech (FBIO) amend and how much is outstanding?

Fortress Biotech entered into a First Amendment to its Credit Agreement originally dated July 25, 2024 with Oaktree Fund Administration as administrative agent. The company initially borrowed $35.0 million under this agreement and, as of the report date, has approximately $29.5 million outstanding under the loan.

How did the amendment change Fortress Biotech (FBIO)'s loan maturity and repayment schedule?

The amendment extends the loan’s maturity from July 25, 2027 to June 30, 2028, with quarterly interest payments until maturity. Principal will now be repaid based on the outstanding balance as of September 30, 2027: 12.5% is due on September 30, 2027, another 12.5% on December 31, 2027, 37.5% on March 31, 2028, and the remaining 37.5% on the new maturity date.

What are the new Journey Medical net sales covenants in Fortress Biotech (FBIO)'s loan?

The financial covenant now requires Journey Medical Corporation’s consolidated product net sales on a trailing twelve-month basis to be at least $60.0 million as of December 31, 2025, $65.0 million as of March 31, 2026, $70.0 million as of June 30, 2026, $75.0 million as of September 30, 2026, and $80.0 million as of December 31, 2026 and each fiscal quarter-end thereafter. Failure to meet these levels constitutes an event of default, subject to cure rights, but the covenant does not apply when the loan’s outstanding principal is less than or equal to $10.0 million.

What warrants did Fortress Biotech (FBIO) issue to its lenders in connection with the amendment?

In connection with the amendment, Fortress Biotech granted warrants to the lenders to purchase up to 600,000 shares of common stock at an exercise price of $2.62 per share. The warrants are immediately exercisable, expire on July 25, 2031, include customary anti-dilution adjustments and a price-reset feature if new equity is issued below the current exercise price, and may be net exercised at the holder’s election.

Will Fortress Biotech (FBIO) register the shares underlying the new warrants?

The company agreed to file a registration statement to register the resale of the shares of common stock issuable upon exercise of the warrants. The warrants themselves are being issued as unregistered securities in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

What happens if Journey Medical fails to meet the minimum net sales test under the Fortress Biotech (FBIO) loan?

Failure to comply with the Minimum Net Sales Test for Journey Medical’s product net sales will result in an event of default under the loan, subject to specified cure rights for the company. This covenant-based default test applies only when the outstanding principal balance of the loan exceeds $10.0 million.